---
title: "Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Specific populations questions"
description: "Specific populations questions on Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Gardasil 9 be given during pregnancy? What pregnancy outcomes were seen after Gardasil 9 exposure? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Specific populations questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Gardasil 9](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf)

Specific populations questions that apply to every indication of Gardasil 9 are on [Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), all indications: Specific populations](https://www.evicenter.com/medical-information/gardasil-9/specific-populations).

## Pregnancy and breastfeeding

<a id="gardasil9-pregnancy"></a>

### Can Gardasil 9 be given during pregnancy?

Applies to: Pregnant individuals and individuals exposed to Gardasil 9 shortly before or during pregnancy

> “Safety and effectiveness of GARDASIL 9 have not been established in pregnant women.”

Source: [GARDASIL 9: GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for Health Care Professionals, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/#:~:text=Safety%20and%20effectiveness%20of%20GARDASIL,been%20established%20in%20pregnant%20women.)

> “All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general
> population, the estimated background risk of major birth defects and miscarriage in clinically recognized
> pregnancies is 2% to 4% and 15% to 20%, respectively. There are no adequate and well-controlled
> studies of GARDASIL 9 in pregnant women. Data from GARDASIL are relevant to GARDASIL 9 because
> both vaccines are manufactured using the same process and have overlapping compositions. Data were
> evaluated from pre-licensure studies in which 55 and 62 pregnancies with known outcomes were
> associated with women inadvertently exposed to GARDASIL and GARDASIL 9, respectively. Pregnancy
> Exposure Registry data are available from 1640 and 69 prospectively enrolled women with known
> pregnancy outcomes who were vaccinated with GARDASIL and GARDASIL 9, respectively. Available
> data do not suggest an increased risk of major birth defects and miscarriage in women who received
> GARDASIL or GARDASIL 9.”

Source: [GARDASIL 9: Prescribing information, page 10, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=10)

<a id="gardasil9-pregnancy-outcomes"></a>

### What pregnancy outcomes were seen after Gardasil 9 exposure?

Applies to: Pregnant individuals and individuals exposed to Gardasil 9 shortly before or during pregnancy

> “An analysis was conducted to evaluate pregnancy
> outcomes for pregnancies with onset within 30 days before or after vaccination with GARDASIL 9 or
> GARDASIL. Among such pregnancies, there were 62 and 55 with known outcomes (excluding ectopic”

Source: [GARDASIL 9: Prescribing information, page 10, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=10)

> “pregnancies and elective terminations) for GARDASIL 9 and GARDASIL, respectively, including 44 and
> 48 live births, respectively. The rates of pregnancies that resulted in a miscarriage were 27.4% (17/62)
> and 12.7% (7/55) in subjects who received GARDASIL 9 or GARDASIL, respectively. The rates of live
> births with major birth defects were 0% (0/44) and 2.1% (1/48) in subjects who received GARDASIL 9 or
> GARDASIL, respectively.”

Source: [GARDASIL 9: Prescribing information, page 11, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=11)

> “A six-year pregnancy registry for GARDASIL 9 enrolled 185 women who were exposed to
> GARDASIL 9 within one month prior to the last menstrual period (LMP) or at any time during pregnancy,
> 180 of whom were prospectively followed. After excluding elective terminations (n=1), ectopic
> pregnancies (n=0) and those lost to follow-up (n=110), there were 69 pregnancies (including one twin
> pregnancy) with known outcomes. Of the 69 pregnancies, 5 were in women exposed twice during
> pregnancy. Therefore, there were 74 exposures to GARDASIL 9 during pregnancy: 3 occurred during the
> 30 days prior to LMP, 34 during the first trimester, 13 during the second trimester, 19 during the third
> trimester, and 5 in an unknown trimester. Adverse pregnancy outcomes included 3 miscarriages (all in
> pregnancy exposures during the first trimester) and 3 major birth defects (one each for pregnancy
> exposure during the 30 days prior to LMP, first trimester, and second trimester). Women who were
> exposed twice during pregnancy had 0 miscarriages and 0 major birth defects. These data do not suggest
> an increased risk of major birth defects and miscarriage in women who received GARDASIL 9.”

Source: [GARDASIL 9: Prescribing information, page 11, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf#page=11)

## Related pages
- [Medical information: Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant): Human papillomavirus vaccination](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination)
- [Indication](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/guidelines)
